Nat King

Nat King is an experienced professional in the pharmaceutical industry, currently serving as Associate Director at Ascendis Pharma since November 2021. In this role, Nat focuses on late-stage development, marketing authorization, and early-stage commercialization for Skytrofa® (TransCon™ hGH) and Yorvipath® (TransCon™ PTH). Prior to this position, Nat worked at Novo Nordisk from April 2016 to November 2021, advancing through various roles including Regulatory Professional, Project Manager, and Regulatory Manager, with responsibilities spanning Phase 3 trials, global labeling processes, and regulatory strategy for multiple regions. Nat holds a Master of Science in Chemistry and Organic Synthesis from Københavns Universitet and a Bachelor of Science in Chemistry from The University of Sheffield. Additional experience includes working as a Research Assistant at the University of Copenhagen and teaching English in China.